SK277925B6 - Method of stereoselective preparation of phenylisoserine derivatives - Google Patents
Method of stereoselective preparation of phenylisoserine derivatives Download PDFInfo
- Publication number
- SK277925B6 SK277925B6 SK1451-91A SK145191A SK277925B6 SK 277925 B6 SK277925 B6 SK 277925B6 SK 145191 A SK145191 A SK 145191A SK 277925 B6 SK277925 B6 SK 277925B6
- Authority
- SK
- Slovakia
- Prior art keywords
- formula
- tert
- alcohol
- group
- configuration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Semiconductor Integrated Circuits (AREA)
- Indole Compounds (AREA)
Abstract
Description
Oblasť technikyTechnical field
Vynález sa týka spôsobu stereoselektívnej prípravy derivátov fenyliuoserinu všeobecného vzorca I:The present invention relates to a process for the stereoselective preparation of the phenylioserine derivatives of the general formula I:
NH-CO-RNH-CO-R
v ktorom R znamená fenylový radikál alebo terc.butoxy-radikál a R* znamená ochrannú skupinu hydroxylovej skupiny.wherein R is a phenyl radical or t-butoxy radical and R * is a hydroxyl protecting group.
Vo všeobecnom vzorci I R1 znamená najmä metoxylový radikál, 1-etoxyetylový radikál, benzyloxymetylový radikál, (beta-trimetylsilyletoxy)metylový radikál, tetrahydropyranylový radikál alebo 2,2,2-trichlóretoxýkarbonylový radikál. Výhodne R1 predstavuje l-etoxyetylový radikál.In the general formula, IR 1 is in particular a methoxy radical, a 1-ethoxyethyl radical, a benzyloxymethyl radical, a (beta-trimethylsilylethoxy) methyl radical, a tetrahydropyranyl radical or a 2,2,2-trichloroethoxycarbonyl radical. Preferably R 1 represents a 1-ethoxyethyl radical.
Produkty všeobecného vzorca I sa používajú na prípravu derivátov baccatínu m a 10-deacetylbaccatínu Hl všeobecného vzorca Π:The products of the formula I are used for the preparation of baccatin m and 10-deacetylbaccatin H1 derivatives of the formula Π:
Do reakcie je možné uviesť racemický produkt všeobecného vzorca I a potom rozdeliť diastereoizoméry produktu všeobecného vzorca H, alebo uviesť do reakcie oddelene každý z enantiomérov produktu všeobecného vzorca I a nechať ho takto reagovať s produktom všeobecného vzorca O.The racemic product of formula (I) may be reacted and then the diastereoisomers of the product of formula (H) may be separated, or each of the enantiomers of the product of formula (I) separately reacted and reacted with the product of formula (O).
Podstata vynálezuSUMMARY OF THE INVENTION
Kyselina všeobecného vzorca I (konfigurácia Έ, racemická zmes) sa môže podľa vynálezu získať z benzylamínu.The acid of formula I (configuration Έ, racemic mixture) according to the invention can be obtained from benzylamine.
Uvedený benzylamín sa účinkom činidla umožňujúceho zaviesť benzoylovú skupinu alebo terc.butoxykarbonylovú skupinu prevedie na produkt všeobecného vzorca IV:The benzylamine is converted to the product of formula IV by the action of a benzoyl or tert-butoxycarbonyl group introducing agent:
NH-CO-R αν] v ktorom R má uvedený význam, a tento produkt sa po dvojitej anionizácii nechá reagovať s akroleínom za vzniku alkoholu všeobecného vzorca V:NH-CO-R αν] in which R is as defined above, and this product is reacted with acrolein after a double anion to form an alcohol of formula V:
rr
NH-CO-RNH-CO-R
v ktorom R znamená fenylový radikál alebo terc.butoxy-radikál a R3 znamená atóm vodíka alebo acetylový radikál.wherein R represents a phenyl radical or tert-butoxy radical and R 3 represents a hydrogen atom or an acetyl radical.
Produkty všeobecného vzorca Π, v ktorom R znamená fenylový radikál, zodpovedajú taxolu a 10-deacetyltaxolu a produkty všeobecného vzorca Π, v ktorom R znamená terc.butoxy-radikál, zodpovedajú produktom, ktoré sú opísané v európskom patente EP 253 738.The products of formula Π in which R represents a phenyl radical correspond to taxol and 10-deacetyltaxol and the products of formula Π in which R represents a tert-butoxy radical correspond to those described in European patent EP 253 738.
Produkty všeobecného vzorca H a najmä produkt všeobecného vzorca Π, v ktorom R3 znamená atóm vodíka, ktoré majú konfiguráciu 2’R, 3 S, majú zvlášť zaujímavé protinádorové a antileukemické vlastnosti.The products of formula H and in particular the product of formula Π, wherein R 3 is H, having the configuration 2'R, 3S, have particularly advantageous antitumour and antileukemic properties.
Doterajší stav technikyBACKGROUND OF THE INVENTION
Produkty všeobecného vzorca Π sa môžu získať pôsobením produktu všeobecného vzorca I na derivát taxánu všeobecného vzorca ΠΙ:The products of formula Π can be obtained by treating a taxane derivative of formula ΠΙ with a product of formula I:
V ktorom R5 znamená acetylový radikál alebo ochrannú skupinu hydroxylovej skupiny a R4 znamená ochrannú skupinu hydroxylovej skupiny a následným nahradením ochranných skupín R1 a R4 a prípadne R5 atómom vodíka za podmienok opísaných v J-N. Denis a kol. v J. Amer. Chem. Soc., 770(17)5917-5919 (1988).Wherein R 5 is an acetyl radical or a hydroxyl protecting group and R 4 is a hydroxyl protecting group, followed by replacement of the protecting groups R 1 and R 4 and optionally R 5 with a hydrogen atom under the conditions described in JN. Denis et al. in J. Amer. Chem. Soc., 770 (17) 5917-5919 (1988).
v ktorom R má vyššie uvedený význam, vo forme zmesi konfigurácií E a Z, obsahujúcej predovšetkým konfiguráciu E:in which R is as defined above, in the form of a mixture of configurations E and Z, comprising in particular the configuration E:
NH-CO-RNH-CO-R
CéHs OHC 6 H 8 OH
Alkohol všeobecného vzorca Va, ktorý sa oddelil zo zmesi konfigurácií E a Z, sa po ochránení hydroxylovej skupiny oxiduje na kyselinu všeobecného vzorcaThe alcohol of the formula Va, which is separated from the mixture of configurations E and Z, is oxidized to the acid of the formula after protection of the hydroxyl group
I.I.
Produkt všeobecného vzorca IV je všeobecne možné získať pôsobením činidla umožňujúceho zaviesť benzoylovú skupinu alebo terc.butoxykarbonylovú skupinu, ktorým je podľa okolností výhodne benzoylchlorid alebo di-terc.butyldikarbonát. Vo všeobecnocti sa pracuje v organickom rozpúšťadle, akým je metylénchlorid, v prítomnosti minerálnej zásady, akou je hydroxid sodný alebo hydrogénuhličitan alebo uhličitan sodný, alebo organickej zásady, akou je trietylamin alebo 4-dimetylaminopyridín, pri teplote 0 až 50°C.The product of formula (IV) is generally obtainable by treatment with a benzoyl or tert-butoxycarbonyl group, which is preferably benzoyl chloride or di-tert-butyldicarbonate. Generally, the reaction is carried out in an organic solvent such as methylene chloride in the presence of a mineral base such as sodium hydroxide or sodium bicarbonate or carbonate, or an organic base such as triethylamine or 4-dimethylaminopyridine at 0 to 50 ° C.
Dvojitá anionizácia produktu všeobecného vzorca IV sa uskutočňuje všeobecne s použitím dvoch ekvivalentov organolítneho derivátu, akým je sek.butyllítium, pričom sa pracuje v bezvodom organickom rozpúšťadle, akým je tetrahydrofurán, pri teplote nižšej ako -50°C, výhodne pri teplote blízkej -78°C.The double anionization of the product of formula (IV) is generally carried out using two equivalents of an organolithium derivative such as sec-butyllithium, operating in an anhydrous organic solvent such as tetrahydrofuran at a temperature below -50 ° C, preferably near -78 ° C.
Všeobecne sa reakcia akroleínu s dianiónom produktu všeobecného vzorca IV uskutočňuje tak, že sa akroleín, výhodne čerstvo destilovaný, pridá k roztoku uvedeného dianiónu produktu všeobecného vzorca IV, ktorý sa predtým ochladil na teplotu blízku -100°C. Po hydrolýze sa získa produkt všeobecného vzorca V vo forme zmesi diastereoizomérov Έ a Z a z tejto zmesi sa oddelí konfigurácia E produktu všeobecného vzorca Va pomocou chromatograíie.In general, the reaction of acrolein with a dianion of the product of formula IV is carried out by adding acrolein, preferably freshly distilled, to a solution of said dianion of the product of formula IV, which has previously been cooled to a temperature near -100 ° C. After hydrolysis, the product of formula V is obtained in the form of a mixture of diastereoisomers Έ and Z and from this mixture the E configuration of the product of formula Va is separated by chromatography.
Ochrana hydroxylovej skupiny alkoholu všeobecného vzorca Va sa uskutočňuje za podmienok, používaných pri príprave éterov a acetalov, napríklad postupmi opísanými v J-N. Denis a kol. v J. Org. Chem., 51, 46-50 (1986).The protection of the hydroxyl group of the alcohol of formula (Va) is carried out under conditions used in the preparation of ethers and acetals, for example by the procedures described in J-N. Denis et al. in J. Org. Chem., 51, 46-50 (1986).
Oxidácia alkoholu všeobecného vzorca Va s chránenou hydroxylovou skupinou sa výhodne uskutočňuje pomocou jodistanu alkalického kovu (jodistanu sodného) v prítomnosti katalytického množstva rutenitej soli (chlorid rutenitý) a hydrogénuhličitanu sodného, pričom sa pracuje vo vodno-organickom prostredí, akým je napríklad zmes tetractúórmetánu, acetonitrilu a vody. Všeobecne sa táto reakcia uskutočňuje pri teplote blízkej 20°C.The oxidation of the hydroxyl-protected alcohol of the formula (Va) is preferably carried out with an alkali metal periodate (sodium periodate) in the presence of a catalytic amount of ruthenium salt (ruthenium chloride) and sodium bicarbonate, operating in an aqueous-organic environment such as tetracturomethane, acetonitrile. and water. Generally, this reaction is carried out at a temperature near 20 ° C.
Uvedená oxidácia sa môže tiež uskutočňovať pomocou manganistanu draselného, napríklad v prítomnosti adogenu v zmesi pentánu a vody alebo v prítomnosti aliquátu alebo 18-di-cyklohexyl-6-crownu v dichlórmetáne alebo v zmesi pyridínu a vody. Môže sa tiež použiť trietylbenzylamóniumpermanganát v prítomnosti pyridínu v dichlórmetáne.Said oxidation may also be carried out with potassium permanganate, for example in the presence of adogen in a mixture of pentane and water or in the presence of an alquate or 18-dicyclohexyl-6-crown in dichloromethane or a mixture of pyridine and water. Triethylbenzylammonium permanganate can also be used in the presence of pyridine in dichloromethane.
Produkt všeobecného vzorca 1 (konfigurácia E, racemická zmes) sa môže rozštiepiť na svoje enantioméry a najmä na enantiomér 2R,3S, napríklad postupom, opísaným D. Pettersonom v These de l'Université de Lund (Švédsko), str. 27-28 (1989).The product of formula 1 (configuration E, racemic mixture) can be resolved into its enantiomers and in particular to the enantiomer 2R, 3S, for example by the procedure described by D. Petterson in These de l'Université de Lund (Sweden), p. 27-28 (1989).
V nasledujúcej časti opisu bude spôsob podľa vynálezu bližšie objasnený pomocou konkrétnych príkladov jeho uskutočnenia, ktoré však majú iba ilustračný charakter a vlastný rozsah vynálezu, vymedzený formuláciou patentových nárokov, nijako neobmedzujú.In the following, the process according to the invention will be explained in more detail by means of specific examples thereof, which, however, are only illustrative and do not limit the actual scope of the invention as defined by the claims.
Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION
Príklad 1Example 1
Do jednohrdlovej banky s obsahom 50 cm3, s chladičom a magnetickým miešadlom, sa pod atmosférou argónu zavedie 218,5 yul (214,3 mg, 2 milimóly) benzylamínu a 10 cm3 bezvodého dichlórmetánu. K takto získanému roztoku sa pridá 418 /ul (303 mg, 3 milimóly) trietylamínu a v malých dávkach (exotermná reakcia) 524 mg (2,4 milimólu) čistého di-terc.butyldikarbonátu. Keď sa pridávanie ukončí, zmes sa nechá reagovať počas 4 hodín pri teplote blízkej 20°C, následne sa reakčná zmes zriedi 40 cm3 dichlórmetánu. Organická fáza sa štyrikrát premyje 5 cm3 vody a raz 5 cm3 nasýteného vodného roztoku chloridu sodného. Organická fáza sa potom vysuší nad bezvodým síranom sodným. Po filtrácii sa dichlórmetán odstráni pri zníženom tlaku v rotačnej odparke.In a 50 cm 3 single neck flask with condenser and magnetic stirrer, under argon atmosphere, 218.5 µl (214.3 mg, 2 millimoles) of benzylamine and 10 cm 3 of anhydrous dichloromethane are introduced. To this solution was added 418 µl (303 mg, 3 millimoles) of triethylamine and 524 mg (2.4 millimoles) of pure di-tert-butyl dicarbonate in small portions (exothermic reaction). When the addition is complete, the mixture is allowed to react for 4 hours at a temperature in the region of 20 ° C, then the reaction mixture is diluted with 40 cm 3 of dichloromethane. The organic phase is washed four times with 5 cm 3 of water and once with 5 cm 3 of saturated aqueous sodium chloride solution. The organic phase is then dried over anhydrous sodium sulfate. After filtration, the dichloromethane is removed under reduced pressure in a rotary evaporator.
Získaný zvyšok (505 mg) sa vyčistí chromatograficky na stĺpci silikagélu, pričom sa ako elučná sústava použije zmes octanu etylnatého a metylénchloridu v objemovom pomere 5:95. Týmto spôsobom sa získa 406 mg (1,96 milimólov) terc.butylbenzylkarbamátu vo forme bieleho pevného produktu s výťažkom 98 %. Tento produkt má nasledujúce charakteristiky:The residue (505 mg) is purified by chromatography on a silica gel column, eluting with a mixture of ethyl acetate and methylene chloride (5:95 by volume). 406 mg (1.96 mmol) of tert-butylbenzylcarbamate are obtained in the form of a white solid in a yield of 98%. This product has the following characteristics:
- teplota topenia: 55,5 - 56,5’C(hexán);- melting point: 55.5 - 56.5 ° C (hexane);
- infračervené spektrum (film):- infrared spectrum (film):
charakteristické absorpčné pásy pri:characteristic absorption bands at:
3350,3315, 3080, 3060, 3040, 3010,2980,2960, 2930,1680, 1550, 1450, 1442,1395,1370, 1315, 1290,1255,1180, 1140, 1080,1055,1035, 950, 930,918, 865,770, 750, 725 a 700 cm-1;3350.3315, 3080, 3060, 3040, 3010.2980.2960, 2930.1680, 1550, 1450, 1442.1395.1370, 1315, 1290.1255.1180, 1140, 1080.1055.1035, 950, 930.918, 865,770, 750, 725 and 700 cm -1 ;
- H-nukleáme magnetickorezonančné spektrum: /300 MHz; CDC1 j; chemické posuny v ppm; väzbová konštanta J v Hz/1,46 /s, 9HA@ 1 H NMR (CDCl3): 300 MHz; CDCl 1; chemical shifts in ppm; coupling constant J in Hz / 1.46 / s, 9HA
4,3/dJ=5,7^H/; 4,84/s šír., ÍHA 13 7,22-7,34 Λη, 5HA4.3 / d J = 5.7; H /; 4.84 / sec. Width, IHA 13 7.22-7.34 Λη, 5HA
- C-nukleáme magnetickorezonančné spektrum:- C-nuclear magnetic resonance spectrum:
/CDC13/ 28,38 /CH3A 44,69 /CH2A(CDCl 3 / 28.38) CH 3 A 44.69 / CH 2 A
79,43 /CA 127,27 /CHA, 127,41 /CHA, 128,54 /CHA 138,93 /CA 155,84 /C/.79.43 (CA 127.27 / CHA, 127.41 / CHA, 128.54 / CHA 138.93 (CA 155.84 / C).
Príklad 2Example 2
Do jednohrdlovej banky s obsahom 250 cm3, nachádzajúcej sa pod atmosférou argónu a vybavenej magnetickým miešadlom, sa postupne zavedie 4,2 g (20,3 milimólu) terc.butylbenzylkarbamátu, 40 cm3 bezvodého tetrahydrofuránu a 6,5 cm3 (5,0 g, 43 milimólov) tetrametyletyléndiaminu. Získaný roztok sa ochladí na teplotu -78°C, následne sa k nemu po kvapkách pridá 60 cm3 (60 milimólov) IM roztoku sek.butyllítia v hexáne. Zmes sa nechá reagovať pri uvedenej teplote počas 3 hodín, následne sa ochladí na teplotu -100°C. Pridá sa čerstvo destilovaný akroleín v množstve 3 cm3 (2,5 g, 44,9 milimólov) a zmes sa nechá reagovať pri uvedenej teplote počas 3 a 4 minút a potom ešte počas jednej hodiny pri teplote -78°C. Získaná reakčná zmes sa potom hydrolyzuje pri teplote -78°C 20 cm3 vody a potom extrahuje dvakrát 30 cm3 éteru. Organické fázy sa zlúčia a potom premyjú dvakrát 20 cm3 vody a raz 10 cm3 nasýteného vodného roztoku chloridu sodného. Zlúčené organické fázy sa potom vysušia nad bezvodým síranom sodným. Po filtrácii sa rozpúšťadlá odoženú pri zníženom tlaku. Získaný zvyšok (11, 6 g) sa vyčisti na stĺpci silikagélu, pričom sa ako elučná sústava použije zmes metylénchloridu a éteru v objemovom pomere 95:5.4.2 g (20.3 millimoles) of tert-butylbenzylcarbamate, 40 cm 3 of anhydrous tetrahydrofuran and 6.5 cm 3 (5 cm 3 ) are successively introduced into a 250 cm 3 single-necked flask equipped with a magnetic stirrer. 0 g, 43 millimoles) of tetramethylethylenediamine. The solution obtained is cooled to -78 ° C and then 60 cm 3 (60 millimoles) of a 1M solution of sec-butyllithium in hexane are added dropwise. The mixture was allowed to react at this temperature for 3 hours, then cooled to -100 ° C. Freshly distilled acrolein (3 cm 3) (2.5 g, 44.9 millimoles) was added and the mixture was allowed to react at the same temperature for 3 and 4 minutes and then for one hour at -78 ° C. The reaction mixture obtained is then hydrolysed at -78 DEG C. with 20 cm @ 3 of water and then extracted twice with 30 cm @ 3 of ether. The organic phases are combined and then washed twice with 20 cm 3 of water and once with 10 cm 3 of saturated aqueous sodium chloride solution. The combined organic phases are then dried over anhydrous sodium sulfate. After filtration, the solvents were stripped off under reduced pressure. The residue (11.6 g) was purified on a silica gel column using a 95: 5 mixture of methylene chloride and ether as the eluent.
V 49 % výťažku sa získa 2,606 g (9,91 milimólu) I -fenyl-1 -terc.butoxykarbonylamino-2-hydroxy-3-buténu vo forme zmesi diastereoizomérov Έ a Z v pomere 6:1.In a yield of 49%, 2.606 g (9.91 mmol) of 1-phenyl-1-tert-butoxycarbonylamino-2-hydroxy-3-butene are obtained as a 6: 1 mixture of diastereoisomers Έ and Z.
Diastereoizomér konfigurácie E* sa oddelí od diastereoizoméru konfigurácie Z chromatografiou na stĺpci silikagélu, pričom sa ako elučná sústava použije zmes éteru, hexánu a metylénchloridu v objemovom pomere 5:45:50.The diastereoisomer of the E * configuration is separated from the diastereoisomer of the Z configuration by chromatography on a silica gel column, eluting with a mixture of ether, hexane and methylene chloride (5:45:50 by volume).
Diastereoizomér konfigurácie Z má nasledujúce charakteristiky:The diastereoisomer of the Z configuration has the following characteristics:
- teplota topenia: 86,5 - 88°C (hexán);mp 86.5-88 ° C (hexane);
- infračervené spektrum (film): charakteristické absorpčné pásy:- infrared (film): characteristic absorption bands:
3400,2975, 2920,1690, 1500, 1450,1390,1365, 1250, 1175,1080,1050, , 1020,995,920,755 a 700 cm'1;3400, 2975, 2920, 1690, 1500, 1450, 1390, 1365, 1250, 1175, 1080, 1050, 1020, 995, 920, 755 and 700 cm -1 ;
- H-nukleáme magnetickorezonančné spektrum:- H-nuclear magnetic resonance spectrum:
/300 MHz; CDCIy, chemické posuny v ppm;/ 300 MHz; CDCl 3, chemical shifts in ppm;
SK 277925 Β6SK 277925-6
N(%)N (%)
5,325.32
5,345.34
H(%) 8,04 7,98H (%) 8.04 7.98
C(%)C (%)
68,4168.41
68,15 väzbové konštanty J v Hz/ 1,40 /s, 9H/; 1,9 /s šir.,lH/; 4,38 /pst,J = 4,6 a 4,8,1 H/; 4,70 /s šír., 1ΗΛ 520 /dt,J = 1,4 a 10,5, ÍHA, 526 /s šír., ÍHA, 5,34 /dt,J = 1,4 a 172, ÍHA, 5,86/ddd.J = 5,4,10,5 a 1721,ÍHA, n 724-7,37 άη, 5HA,68.15 coupling constants J in Hz (1.40 (s, 9H); 1.9 (s broad, 1H); 4.38 (pst, J = 4.6 and 4.8, 1H); 4.70 / s, 1ΗΛ520 / dt, J = 1.4 and 10.5, IHA, 526 / s, IHA, 5.34 / dt, J = 1.4 and 172, IHA, 5 , 86 / ddd.J = 5,4,10,5 and 1721, IHA, n 724-7,37 years, 5HA,
- C-nukleáme magnetickorezonančné spektrum:- C-nuclear magnetic resonance spectrum:
/CDC13/ 28,12 /CH3A, 58,74 /CHA,/ CDCl 3 / 28.12 / CH 3 A, 58.74 / CHA,
75,33 /CHA, 79,58 /CA, 116,36 /CHjA, 126,69 /CHA, 12726 /CHA, 128,32 /CHA, 137,17 /CHA, 139,96 /CA, 155,89 /CA,75.33 (CHA, 79.58 / CA, 116.36 / CH3, 126.69 / CHA, 12726 / CHA, 128.32 / CHA, 137.17 / CHA, 139.96 (CA, 155.89) CA
- hmotnostné spektrum ä.c.//NH3 + izobután/: 321 /M++izobutánA, 281 /MH++NH3A 264 /MH*. základný píkA, 246,225,208,190,64, 124,106;- mass spectrum ä.c .// NH 3 + isobutane /: 321 / M + + isobutane A, 281 (MH + + NH 3 A 264 / MH +). base peak A, 246,225,208,190,64, 124,106;
- elementárna analýza: vypočítané nájdené- elemental analysis: calculated found
Diastereoizomér Z má nasledujúce charakteristiky:Diastereoisomer Z has the following characteristics:
- infračervené spektrum (film):- infrared spectrum (film):
charakteristické absorpčné pásy:characteristic absorbent bands:
3370, 3060,2975,2920, 1680, 1530, 1470, 1290, 1250, 1170, 1040,1000, 930, 900, 870, 840, 755 t a 700 cm”l;3370, 3060, 2975, 2920, 1680, 1530, 1470, 1290, 1250, 1170, 1040, 1000, 930, 900, 870, 840, 755 t and 700 cm -1;
- H-nukleáme magnetickorezonančné spektrum:- H-nuclear magnetic resonance spectrum:
/300 MHz; CDC13; chemické posuny v ppm; väzbové konštanty J v Hz/1,41 /s, 9HA, 1,8/s šir.JH/,/ 300 MHz; CDC1 3; chemical shifts in ppm; coupling constants J in Hz (1.41 / s, 9HA, 1.8 (s broad JH)),
4.43 /psq,J = 0,9 a 4,4, ÍHA, 4,78 /s šir., ÍHA,4.43 / psq, J = 0.9 and 4.4, IHA, 4.78 / s broad, IHA,
5,18/dt,J = 1,2 a 10,5, ÍHA, 524 /s šir., ÍHA, 526/dt,J = 12 a 17,ÍHA, 5,71 /ddd,J = 5,5,10,5 a 17,ÍHA, |3 724-7,36 ta, 5HA,5.18 / dt, J = 1.2 and 10.5, IHA, 524 / s broad, IHA, 526 / dt, J = 12 and 17, IHA, 5.71 / ddd, J = 5.5, 10.5 and 17, IHA, | 3,724-7.36 ta, 5HA,
- C-nukleáme magnetickorezonančné spektrum:- C-nuclear magnetic resonance spectrum:
/CDC13/ 2823 /CH3/; 5922 /CHA,/ CDC1 3/2823 / CH3 /; 5922 / CHA
75.33 /CHA, 79,85 /CA, 117,06 /CH2A,75.33 / CHA, 79.85 / CA, 117.06 / CH 2 A,
12729 /CHA, 127,56 /CHA,12729 / CHA, 127.56 / CHA
128.33 /CHA, 13627 /CHA, 138,14 /CA, 155,61 /CA,128.33 / CHA, 13627 / CHA, 138.14 / CA, 155.61 / CA,
C(%) 68,41C (%) 68.41
68.4368.43
N (%) 5,32 5,08.N (%) 5.32 5.08.
- elementárna analýza: vypočítané nájdené- elemental analysis: calculated found
H(%) 8,04 8,14H (%) 8.04 8.14
Príklad 3Example 3
Do jednohrdlovej banky s obsahom 50 cm3, nachádzajúcej sa pod atmosférou argónu a vybavenej magnetickým miešadlom, sa postupne zavedie 526 mg (2,0 milimóly) l-fenyl-l-terc.butoxy-karbonylamino-2-hydroxy-3-buténu konfigurácie Έ, 20 cm3 bezvodého metylénchloridu, 1,9 cm3 (20,0 milimólov) čerstvo destilovaného etylvinylétem a 502 mg (02 milimólov) pyridinium-p-toluénsulfonátu. Výsledná homogénna reakčná zmes sa nechá reagovať počas 4,5 hodiny pri teplote blízkej 20 °C. Ihneď ako je reakcia ukončená, pridá sa jedna kvapka pyridínu a reakčná zmes sa zriedi 60 cm3 metylénchloridu. Organická fáza sa dvakrát premyje vodou a dvakrát nasýteným vodným roztokom chloridu sodného, následne sa vysuší nad bezvodým síranom sodným. Po filtrácii sa rozpúšťadlá odstránia pri zníženom tlaku v rotačnej odparke. Získaný zvyšok sa vyčistí na stĺpci silikagélu, pričom sa ako elučná sústava použije zmes hexánu a éteru v objemovom pomere 8:2. V 87 % výťažku sa získa 580 mg (1,73 milimólu) 1 -fenyl-1 -terc. butoxykarbonylamino-2-( 1 -etoxyetoxy )-3-buténu vo forme oboch epimérov v pomere 55/45, ktoré majú nasledujúce charakteristiky:In a 50 cm 3 , one-necked flask, under argon and equipped with a magnetic stirrer, was gradually introduced 526 mg (2.0 millimoles) of 1-phenyl-1-tert-butoxycarbonylamino-2-hydroxy-3-butene of configuration Cm, 20 cm 3 of anhydrous methylene chloride, 1.9 cm 3 (20.0 millimoles) freshly distilled with ethyl vinyl acetate and 502 mg (02 millimoles) of pyridinium p-toluenesulfonate. The resulting homogeneous reaction mixture is allowed to react for 4.5 hours at a temperature near 20 ° C. Once the reaction is complete, one drop of pyridine is added and the reaction mixture is diluted with 60 cm 3 of methylene chloride. The organic phase is washed twice with water and twice with saturated aqueous sodium chloride solution and then dried over anhydrous sodium sulphate. After filtration, the solvents are removed under reduced pressure in a rotary evaporator. The residue is purified on a silica gel column, eluting with a hexane / ether (8/2, v / v) mixture. In 87% yield, 580 mg (1.73 mmol) of 1-phenyl-1-tert. butoxycarbonylamino-2- (1-ethoxyethoxy) -3-butene in the form of both epimers in the ratio 55/45, having the following characteristics:
- teplota topenia: 66 - 72°C;melting point: 66-72 ° C;
- infračervené spektrum (film): charakteristické absorpčné pásy pri:- infrared spectrum (film): characteristic absorption bands at:
3370,2970,2925,2875, 1680,1520, 1495,1365, 1285,1250, 1170, 1080, 1050,1005,955, 930,890, t 870,755 a 705 cm'1;3370,2970,2925,2875, 1680,1520, 1495,1365, 1285,1250, 1170, 1080, 1050,1005,955, 930,890, t 870,755 and 705 cm -1 ;
- H-nukleáme magnetickorezonančné spektrum:- H-nuclear magnetic resonance spectrum:
/300 MHz; CDC13; chemické posuny v ppm; väzbové konštanty J v Hz/0,9tain./ a 1,07/maj.//2t, J=7,3HA, l,05tain./a 122 taaj./Z2d,J=5,3tain./ a 5,4 taaj./,3HA, l,40/s,9HA, 2,90-2,98 a 3,05-3,5 lta2H/; 4,16 a 423/2psdd,J=6,6 a 7,ÍHA, 4,31tain./a4,62 taaj.//2q,J=5,3/min./ a 5,4 taaj./,ΙΗΑ, 4,71 taaj. a 4,74tain./Z2m,lHA, 522 a 523/2dt,J=12 a 10,5,ÍHA, 5,25a5,30Z2dt,J=l2a 17,4, ÍHA, 5,37 a 5,442m,ÍHA, 5,77tain./a 5,9+taaj./2ddd,J= = 7,10,5 a 17,4, ÍHA, 7,177,37ta,5HA/ 300 MHz; CDC1 3; chemical shifts in ppm; coupling constants J in Hz (0.9tain) and a 1.07 (possessing) 2t, J = 7.3HA, 1.55tain / and 122 taaj./Z2d, J=5.3tain./ and 5, 4 taut / 3HA, 1.40 (s, 9HA, 2.90-2.98 and 3.05-3.5 lta2H); 4,16 and 423 / 2psdd, J = 6,6 and 7, IHA, 4,31tain / a4,62 taaj.//2q, J=5,3/min./ and 5,4 taaj./,ΙΗΑ , 4.71 taaj. and 4.74tains / Z2m, 1HA, 522 and 523 / 2dt, J = 12 and 10.5, IHA, 5.25 and 5.30Z2dt, J = 12 and 17.4, IHA, 5.37 and 5.442m, IHA, 5.77tain / a 5.9 + ta / 2ddd, J = 7.10.5 and 17.4, IHA, 7,177.37ta, 5HA
- elementárna analýza: C (%) vypočítané 68,03 nájdené 68,00Elemental analysis: C (%) calculated 68.03 found 68.00
Príklad 4Example 4
Do jednohrdlovej banky s obsahom 15 cm3, udržovanej pod atmosférou argónu a vybavenej magnetickým miešadlom, sa zavedie 251 mg (0,75 milimólu) konfigurácie E 1-fenyl-l-terc.butoxykarbonylamino-2-(l-etoxyetoxy )-3-buténu vo forme roztoku v 1,5 cm3 acetonitrilu. Potom sa postupne pridá 1,5 cm3 tetrachlórmetánu, 225 cm3 destilovanej vody a za silného miešania 409,5 mg (4,875 milimólu) hydrogénuhličitanu sodného. Potom sa pridá v malých dávkach 882 mg (4,125 milimólu) jodistanu sodného. Reakčná zmes sa nechá reagovať za miešania počas 5 minút (vývoj plynu), následne sa k nej naraz pridá 25,1 mg (10 % hmotn.) chloridu ruteničitého. Zmes sa nechá reagovať za silného miešania (sčernalá silne heterogénna zmes) počas 48 hodín pri teplote blízkej 20°C.In a 15 cm 3 single neck flask maintained under argon and equipped with a magnetic stirrer, 251 mg (0.75 millimoles) of the E configuration of 1-phenyl-1-tert-butoxycarbonylamino-2- (1-ethoxyethoxy) -3- butene as a solution in 1.5 cm 3 of acetonitrile. Thereafter, 1.5 cm @ 3 of carbon tetrachloride, 225 cm @ 3 of distilled water are added in succession, and sodium bicarbonate (409.5 mg, 4.875 mmol) is added with vigorous stirring. 882 mg (4.125 millimoles) of sodium periodate are then added in small portions. The reaction mixture was allowed to react with stirring for 5 minutes (gas evolution) followed by the addition of 25.1 mg (10 wt%) of ruthenium chloride in one portion. The mixture was allowed to react with vigorous stirring (blackish strongly heterogeneous mixture) for 48 hours at a temperature near 20 ° C.
Reakčná zmes sa potom zriedi vodou tak, aby sa získal celkový objem 12 cm3. Čierna zásaditá vodná fáza sa trikrát extrahuje 20 cm3 éteru. Zásaditá fáza sa potom ochladí na teplotu 0°C, následne sa k nej v prítomnosti 30 cm3 metylénchloridu a za silného miešania po kvapkách pridá 2M vodný roztok kyseliny chlorovodíkovej v množstve 3 cm3. Získaná kyslá vodná fáza sa extrahuje 35 cm3 metylénchloridu. Organické fázy sa zlúčia a premyjú trikrát 8 cm3 vody, raz 10 cm3 nasýteného vodného roztoku chloridu sodného Organické fázy sa potom vysušia nad zmesou síranu sodného a síranu horečnatého v objemovom pomere 1:1a prefiltrujú cez celit pri zníženom tlaku. Rozpúšťadlá sa potom odstránia pri zníženom tlaku na zmenšenie objemu na 5 až 8 crn^. Tento zvyšok sa vysuší na molekulárnom site 4Ä. Organická fáza sa oddelí od molekulárneho sita a zvyšok rozpúšťadla sa odstráni pri zníženom tlaku v rotačnej odparke.The reaction mixture is then diluted with water to give a total volume of 12 cm 3 . The black basic aqueous phase is extracted three times with 20 cm @ 3 of ether. The basic phase is then cooled to 0 ° C, followed by the dropwise addition of a 2M aqueous hydrochloric acid solution of 3 cm 3 dropwise in the presence of 30 cm 3 of methylene chloride. The acidic aqueous phase obtained is extracted with 35 cm @ 3 of methylene chloride. The organic phases are combined and washed three times with 8 cm @ 3 of water, once with 10 cm @ 3 of saturated aqueous sodium chloride solution. The organic phases are then dried over a 1: 1 by volume mixture of sodium sulfate and magnesium sulfate and filtered through celite under reduced pressure. The solvents are then removed under reduced pressure to reduce the volume to 5 to 8 cm 3. This residue is dried on a 4Ä molecular sieve. The organic phase is separated from the molecular sieve and the residual solvent is removed under reduced pressure in a rotary evaporator.
V 77 % výťažku sa získa 205 mg (0,58 milimólu) čistej konfigurácie E kyseliny 3-fenyl-3-terc.butoxykarbonylamino-2-(l-etoxyetoxy)propiónovej vo forme svetlo žltého oleja, ktorý má nasledujúce charakteristiky:In 77% yield, 205 mg (0.58 mmol) of pure configuration E of 3-phenyl-3-tert-butoxycarbonylamino-2- (1-ethoxyethoxy) propionic acid is obtained as a pale yellow oil having the following characteristics:
- infračervené spektrum (film): charakteristické absorpčné pásy pri:- infrared spectrum (film): characteristic absorption bands at:
3700-2200, 3060,2980,3700-2200, 3060.2980,
2930, 2850, 1720,1660,2930, 2850, 1720, 1660,
1602,1590, 1500,1450,1602.1590, 1500.1450,
1400,1370, 1280,1250,1400.1370, 1280.1250,
1170,1080,1050,1030, , 950, 930, 890 a 700 cm-1;1170, 1080, 1050, 1030, 950, 930, 890 and 700 cm -1 ;
- H-nukleáme magnetickorezonančné spektrum:- H-nuclear magnetic resonance spectrum:
/300 MHz; CDClj; chemické posuny v ppm; vflzbové konštanty J v Hz// 300 MHz; CDCl; chemical shifts in ppm; frequency constants J in Hz /
0,81 a 1,04 /2t,J=7, 3H/;0.81 and 1.04 (2t, J = 7.3H);
1,18 a 1,20 /2d,J=5,4, 3HZ;1.18 and 1.20 / 2d, J = 5.4, 3HZ;
1,42 /s,9H/;1.42 (s, 9H);
2,60-2,88 a 3,15-3,52/m^H/,2.60-2.88 and 3.15-3.52 (m ^ H),
4,35-4,50 a 4,65-4,80/m^H/; 5,29/s šir .lH/, 5,72/s šir.,1 H/; 7,13-7,38An,5H/; 8,52/s šir .lHZ.4.35-4.50 and 4.65-4.80 (m, 1H); 5.29 (s broad, 1H), 5.72 (s broad, 1H); 7,13-7,38An, 5 H /; 8.52 / s W1H.
Claims (4)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9006368A FR2662440B1 (en) | 1990-05-22 | 1990-05-22 | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES. |
Publications (1)
Publication Number | Publication Date |
---|---|
SK277925B6 true SK277925B6 (en) | 1995-08-09 |
Family
ID=9396838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1451-91A SK277925B6 (en) | 1990-05-22 | 1991-05-16 | Method of stereoselective preparation of phenylisoserine derivatives |
Country Status (23)
Country | Link |
---|---|
US (1) | US5290957A (en) |
EP (1) | EP0530286B1 (en) |
JP (1) | JPH05506864A (en) |
AT (1) | ATE109456T1 (en) |
AU (1) | AU648319B2 (en) |
CA (1) | CA2079313A1 (en) |
CZ (1) | CZ279927B6 (en) |
DE (1) | DE69103265T2 (en) |
DK (1) | DK0530286T3 (en) |
ES (1) | ES2057899T3 (en) |
FI (1) | FI924568A0 (en) |
FR (1) | FR2662440B1 (en) |
HU (1) | HU212728B (en) |
IE (1) | IE64276B1 (en) |
IL (1) | IL98190A (en) |
NO (1) | NO179942C (en) |
NZ (1) | NZ238206A (en) |
PT (1) | PT97745B (en) |
RU (1) | RU2091368C1 (en) |
SK (1) | SK277925B6 (en) |
WO (1) | WO1991017977A1 (en) |
YU (1) | YU89691A (en) |
ZA (1) | ZA913828B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658510B1 (en) * | 1990-02-21 | 1992-04-30 | Rhone Poulenc Sante | NEW DERIVATIVE OF BETA-PHENYLISOSERINE, ITS PREPARATION AND ITS USE. |
KR930702323A (en) * | 1991-07-17 | 1993-09-08 | 하지메 나까가와 | Compound having antitumor activity (NSC-LSC1) and preparation method thereof |
FR2680506B1 (en) * | 1991-08-19 | 1994-09-02 | Rhone Poulenc Rorer Sa | PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERIN DERIVATIVES AND THEIR USE. |
US6794523B2 (en) | 1991-09-23 | 2004-09-21 | Florida State University | Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them |
US6018073A (en) * | 1991-09-23 | 2000-01-25 | Florida State University | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
US5739362A (en) * | 1991-09-23 | 1998-04-14 | Florida State University | Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them |
KR960006762B1 (en) * | 1992-02-29 | 1996-05-23 | 삼성전자주식회사 | 2-dimensional data scanning selecting circuit for image coding |
FR2696454B1 (en) * | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for the stereoselective preparation of a beta-phenylisoserine derivative and its use for the preparation of Taxane derivatives. |
IL107950A (en) | 1992-12-15 | 2001-04-30 | Upjohn Co | 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
ES2145829T3 (en) * | 1993-06-11 | 2000-07-16 | Upjohn Co | ANTINEOPLASIC USE OF DELTA 6,7-TAXOLS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US6005120A (en) * | 1993-07-20 | 1999-12-21 | Florida State University | Tricyclic and tetracyclic taxanes |
US5405972A (en) * | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
IL127599A (en) * | 1994-01-28 | 2004-06-01 | Upjohn Co | Process for preparing isotaxol analogs |
BR9808697A (en) * | 1997-04-28 | 2000-07-11 | Rhone Poulenc Rorer Sa | Process to inhibit the growth of a tumor, defective adenovirus vector, virus vector, use of it, and pharmaceutical composition |
FR2794771B1 (en) * | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | RECOMBINANT ADENOVIRUSES ENCODING THE IODINE SPECIFIC TRANSPORTER (NIS) |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
CA2772681C (en) * | 2009-09-23 | 2017-01-03 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | Process for manufacture of n-acylbphenyl alanine |
PT2753355T (en) | 2011-09-08 | 2019-02-01 | Univ New York | Oncolytic herpes simplex virus and therapeutic uses thereof |
US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
CA2874521A1 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
WO2014014518A1 (en) | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
EP2968406A4 (en) | 2013-03-14 | 2016-10-26 | Icahn School Med Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
WO2015050844A1 (en) | 2013-10-01 | 2015-04-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer with atovaquone-related compounds |
WO2015149006A2 (en) | 2014-03-27 | 2015-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
US10967015B2 (en) | 2015-06-15 | 2021-04-06 | New York University | Method of treatment using oncolytic viruses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US4775782A (en) * | 1987-09-30 | 1988-10-04 | Ncr Corporation | Checkout counter with remote keyboard writing pad and display |
FR2629819B1 (en) * | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF BACCATIN III AND DESACETYL-10 BACCATIN III DERIVATIVES |
IL95436A (en) * | 1989-08-23 | 1996-07-23 | Centre Nat Rech Scient | Method for the preparation of phenzlisoserine derivatives |
-
1990
- 1990-05-22 FR FR9006368A patent/FR2662440B1/en not_active Expired - Lifetime
-
1991
- 1991-05-16 SK SK1451-91A patent/SK277925B6/en unknown
- 1991-05-16 CZ CS911451A patent/CZ279927B6/en unknown
- 1991-05-20 IL IL9819091A patent/IL98190A/en not_active IP Right Cessation
- 1991-05-21 IE IE173791A patent/IE64276B1/en not_active IP Right Cessation
- 1991-05-21 ZA ZA913828A patent/ZA913828B/en unknown
- 1991-05-21 HU HU9203651A patent/HU212728B/en not_active IP Right Cessation
- 1991-05-21 WO PCT/FR1991/000406 patent/WO1991017977A1/en active IP Right Grant
- 1991-05-21 DE DE69103265T patent/DE69103265T2/en not_active Expired - Fee Related
- 1991-05-21 US US07/949,548 patent/US5290957A/en not_active Expired - Fee Related
- 1991-05-21 ES ES91910270T patent/ES2057899T3/en not_active Expired - Lifetime
- 1991-05-21 YU YU89691A patent/YU89691A/en unknown
- 1991-05-21 NZ NZ238206A patent/NZ238206A/en unknown
- 1991-05-21 EP EP91910270A patent/EP0530286B1/en not_active Expired - Lifetime
- 1991-05-21 AT AT91910270T patent/ATE109456T1/en not_active IP Right Cessation
- 1991-05-21 CA CA002079313A patent/CA2079313A1/en not_active Abandoned
- 1991-05-21 RU RU9192016318A patent/RU2091368C1/en active
- 1991-05-21 DK DK91910270.7T patent/DK0530286T3/en active
- 1991-05-21 AU AU79693/91A patent/AU648319B2/en not_active Ceased
- 1991-05-21 JP JP91509580A patent/JPH05506864A/en active Pending
- 1991-05-22 PT PT97745A patent/PT97745B/en not_active IP Right Cessation
-
1992
- 1992-10-09 FI FI924568A patent/FI924568A0/en not_active Application Discontinuation
- 1992-11-20 NO NO924488A patent/NO179942C/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK277925B6 (en) | Method of stereoselective preparation of phenylisoserine derivatives | |
US5292921A (en) | Process for the enantioselective preparation of phenylisoserine derivatives | |
DE69001732T2 (en) | Process for the enantioselective production of phenylisoserine derivatives. | |
FI109796B (en) | The metal | |
DE69404991T2 (en) | METHOD FOR PRODUCING AN OXAZOLIDINE CARBONIC ACID USEFUL FOR THE PRODUCTION OF THERAPEUTIC TAXOIDS | |
US5304670A (en) | Process for the enantioselective preparation of phenylisoserine derivatives | |
RU2109010C1 (en) | Derivative of $$$-phenylisoserine, method of its stereoselective synthesis, the parent compound for its synthesis, method of synthesis of taxane and intermediate products | |
EP2125765A1 (en) | Method of preparing taxane derivatives and intermediates used therein | |
AU2003267049B2 (en) | Taxane derivatives functionalized at the 14- position and a process for the preparation thereof | |
JPWO2003004515A1 (en) | Method for producing estradiol derivative, intermediate used in the method and method for producing the same |